L-Moses Disrupts PCAF-Brd Histone H3.3 Interaction
Posted On 2021-04-21
Bromodomains proteins (Brds) bind to acetylated lysines (KAc) through the Brd acetyllysine-binding site. Misregulation of these proteins is linked to the onset and progression of multiple disease states. They include cancer, HIV infection, and neuroinflammation. The p300/CBP-associated factor, PCAF (KAT2B), is a multi-domain protein. It contains a single Brd, an N-terminal domain, and a histone acetyltransferase (HAT) domain. The development of a small molecule modulator of PCAF Brd would provide a useful tool for interrogating this potential therapeutic target and allow for dissociation of the roles of the Brd and enzymatic domains in disease. In this study, L-Moses is the first potent, selective, and cell-active PCAF Brd inhibitor. The Kd value is 126 nM. L -45 also shows a clean toxicity profile in primary PBMCs. It also disrupts interactions between PCAF Brd and H3.3 in HEK293 cells, indicating cellular target engagement.
L-Moses disrupts PCAF-Brd histone H3.3 interaction in cells. A co-crystal structure of L-Moses with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. Moreover, L-Moses shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell-permeability, and metabolic stability in human and mouse liver microsomes. Thus, L-Moses has the potential for in vivo use.
In conclusion, L-Moses, the first nanomolar, selective, and cell-active chemical probe of the PCAF bromodomain. In addition, Iterative cycles of rational inhibitor design, in silico docking studies, and synthesis furnished L -45 after generation of a focused PCAF inhibitor library. Furthermore, L-Moses shows a clean toxicity profile in primary PBMCs. It also disrupts interactions between PCAF Brd and H3.3 in HEK293 cells, indicating cellular target engagement.
Moustakim M, et al. Angew Chem Int Ed Engl. 2017 Jan 16;56(3):827-831.